RVL Pharmaceuticals plc (RVLPQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Dec 4, 2025, 4:00 PM EST
900.00%
Market Cap 111.00
Revenue (ttm) 36.92M
Net Income (ttm) -68.27M
Shares Out 111.41M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 600
Average Volume 50,623
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 41.65
RSI 48.35
Earnings Date Aug 14, 2025

About RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and chan... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Brian Markison
Employees 125
Stock Exchange OTCMKTS
Ticker Symbol RVLPQ
Full Company Profile

Financial Performance

In 2022, RVL Pharmaceuticals's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.

Financial Statements

News

There is no news available yet.